Häppölä, Paavo
Havulinna, Aki S.
Tasa, Tõnis
Mars, Nina J.
Perola, Markus
Kallela, Mikko
Milani, Lili
Koskinen, Seppo
Salomaa, Veikko
Neale, Benjamin M.
Palotie, Aarno
Daly, Mark
Ripatti, Samuli
Funding for this research was provided by:
Academy of Finland (312062, 321356)
Estonian Research Council (IUT34-4, PRG184)
Estonian Centre of Excellence in IT (TK148)
Finnish Foundation for Cardiovascular Research
Sigrid Juselius Foundation
University of Helsinki HiLIFE Fellow grant
Article History
Received: 5 March 2020
Accepted: 25 August 2020
First Online: 25 September 2020
Competing interests
: A.P. is a member of Astra Zeneca Genomics Advisory Board. V.S. has participated in a conference trip sponsored by Novo Nordisk and received an honorarium for participating in an advisory board meeting. He also has ongoing research collaboration with Bayer Ltd. (All unrelated to the present study). T.T. is a shareholder, member of the board of directors and management team of Antegenes OÜ. The authors declare no competing interests.